Connect with us

Coronavirus Vaccine

DCGI Gives Nod To Serum Institute To Hold Phase II, III COVID Vaccine Trials

With the aim to expedite the COVID-19 vaccine development, the Drugs Controller General of India (DCGI) has given approval to Serum Institute of India, Pune to conduct Phase II+III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine to be known as COVISHIELD in India

India's Case Fatality Rate (CFR) now stands at 2.11 per cent
Highlights
  • DCGI approved Serum Institute of India’s Phase II+III clinical trials
  • The Vaccine is to be called COVISHEILD in India
  • India's Case Fatality Rate (CFR) stands at 2.11 per cent

New Delhi: The Drugs Controller General of India (DCGI) gave approval to Serum Institute of India, Pune to conduct Phase II+III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India, said the Ministry of Health and Family Welfare on Monday.

The Drugs Controller General of India (DCGI) has given approval to Serum Institute of India, Pune to conduct Phase II+III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India. This will hasten the development of the COVID-19 vaccine, the Health Ministry said in a statement.

The ministry said India’s Case Fatality Rate (CFR) now stands at 2.11 per cent.

Also Read: COVID-19 Vaccine Likely To Come By First Half Of 2021, Says WHO Chief Scientist Dr Soumya Swaminathan

India continues to improve the Case Fatality Rate (CFR), and maintain its global position of having one of the lowest COVID fatality rates. With a further fall, the current CFR touched 2.11 per cent today. This is the outcome of the well-conceived and effectively implemented strategy of “Test, Track and Treat” which has guided COVID management in the country, the ministry said.

India has seen more than 40,574 patients recovered in the last 24 hours. This takes the total recoveries to 11,86,203 and recovery rate to 65.77 per cent amongst COVID-19 patients, the ministry said, adding that the gap between the recovered cases and the active cases has increased to more than 6 lakh.

Presently, it is 6,06,846. This means the actual active caseload is 5,79,357 and all are under medical supervision, the ministry said.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

Click to comment

Leave a Reply

Your email address will not be published.

Folk Music For A Swasth India

RajasthanDay” src=

Reckitt’s Commitment To A Better Future

Expert Blog

हिंदी में पड़े

Latest Posts